公开(公告)号：US20210308084A1

公开(公告)日：2021-10-07

申请号：US17349207

申请日：2021-06-16

Applicant: AJINOMOTO CO., INC.

Inventor： Kyoko MIURA ,  Mai NAKAZAWA ,  Yoshiro KITAHARA

IPC: A61K31/198 ,  A23L33/175

Abstract: Muscle quality-improving agents containing one or more selected from the group consisting of isoleucine, glycine, and cystine can prevent a decline in muscle quality, improve muscle quality even when exercise is limited, and can effectively enhance the effect of exercise even when the exercise is of a level free of undue efforts.

公开(公告)号：US20220088111A1

公开(公告)日：2022-03-24

申请号：US17548044

申请日：2021-12-10

Applicant: AJINOMOTO CO., INC.

Inventor： Yoshiro KITAHARA ,  Yoriko OKAMATSU ,  Kazutaka SHIMBO ,  Naoko ARASHIDA ,  Ayaka SHIRASAWA

IPC: A61K38/01

Abstract: Peptides consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO: 1), LIVTQTMKG (SEQ ID NO: 2), LIVTQTMK (SEQ ID NO: 3), IVTQTMKGL (SEQ ID NO: 4), IVTQTMKG (SEQ ID NO: 5), and VTQTMKGL (SEQ ID NO: 6) are useful for improving intestinal barrier function, for suppressing blood glucose elevation, for improving insulin sensitivity, for promoting FGF21 secretion, for suppressing stress or protecting nerves, or for reducing fatigue.

公开(公告)号：US20170101372A1

公开(公告)日：2017-04-13

申请号：US15389639

申请日：2016-12-23

Applicant: AJINOMOTO CO., INC.

Inventor： Yoshiro KITAHARA ,  Koji OHSUMI ,  Seiji KITAJIMA ,  Shimpei OGAWA

IPC: C07C335/20 ,  C07C335/16

CPC classification number: A61K31/17 ,  A61K31/277 ,  C07C335/16 ,  C07C335/20

Abstract: Sweetness receptor antagonists represented by formula (I): wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.

公开(公告)号：US20220249592A1

公开(公告)日：2022-08-11

申请号：US17726731

申请日：2022-04-22

Applicant: AJINOMOTO CO., INC.

Inventor： Kyoko MIURA ,  Yoshiro KITAHARA ,  Haruka OHASHI

IPC: A61K38/05 ,  A61K38/06 ,  A61K9/00 ,  A61P21/06 ,  A23L33/00 ,  A23L33/18

Abstract: Agents containing γ-glutamyl peptide can prevent a decline in muscle quality and improve muscle quality even when exercise is limited, and further, can effectively enhance the effect of exercise even when the exercise is of a level free of undue efforts.

公开(公告)号：US20190022039A1

公开(公告)日：2019-01-24

申请号：US16144314

申请日：2018-09-27

Applicant: AJINOMOTO CO., INC.

Inventor： Tomohiro FUJII ,  Koji OHSUMI ,  Seiji KITAJIMA ,  Yoshiro KITAHARA

IPC: A61K31/18 ,  C07C311/21 ,  C07C321/14 ,  C07D209/20 ,  C07D295/135 ,  C07D333/20 ,  C07D307/52 ,  C07D271/06 ,  C07C311/13 ,  C07D249/12 ,  C07D213/56 ,  A61P3/04 ,  A61P3/10 ,  A61K31/405 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/381 ,  A61K31/341 ,  A61K31/4245 ,  A61K31/4196 ,  A61K31/4406 ,  A61K45/06

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the present specification, or a salt thereof are useful for the prophylaxis or treatment of diabetes and obesity, and diseases related thereto.